These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30193086)

  • 21. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
    Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
    Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
    Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
    Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S; Wang F; He X; He Y; Li D; Sun S
    Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.
    Shimizu Y; Yoshikawa T; Kojima T; Shoda K; Nosaka K; Mizuno S; Wada S; Fujimoto Y; Sasada T; Kohashi K; Bando H; Endo I; Nakatsura T
    Cancer Sci; 2019 Oct; 110(10):3049-3060. PubMed ID: 31390678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
    Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
    J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer.
    Kono M; Wakisaka R; Komatsuda H; Hayashi R; Kumai T; Yamaki H; Sato R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Kobayashi H; Hayashi T; Takahara M
    Head Neck; 2024 Aug; 46(8):2056-2067. PubMed ID: 38390628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
    Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
    Front Immunol; 2018; 9():2968. PubMed ID: 30631324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
    Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Sasada T; Hattori N; Kohno N; Itoh K
    Cancer Sci; 2015 Oct; 106(10):1257-63. PubMed ID: 26212219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
    Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
    J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
    Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
    Cereda V; Poole DJ; Palena C; Das S; Bera TK; Remondo C; Gulley JL; Arlen PM; Yokokawa J; Pastan I; Schlom J; Tsang KY
    Cancer Immunol Immunother; 2010 Jan; 59(1):63-71. PubMed ID: 19495750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.